G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2024-2033: Size, Share, Growth, Trends, Analysis

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $10.98 billion In 2028 At A CAGR Of 4.6% :
The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical r&d expenditure and government initiatives.

The g-csf (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (g-csf), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs. Major trends in the forecast period include investing extensively in r&d activities for the development of effective and innovative drugs, increasing focus on m&a growth strategies to expand the customer base and geographic markets, establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

G-CSF (Granulocyte Colony Stimulating Factors) Market Major Segments
The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented -
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Key Driver - Rising Prevalence Of Cancer Drives G-Csf Market Growth
The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. G-CSF (granulocyte colony stimulating factor) is a class of growth factors that produce white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF (granulocyte colony stimulating factor) market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=3466&type=smp

Prominent Trend - Strategic Collaborations Drive Innovation In G-Csf Market
Companies in the G-CSF (granulocyte colony stimulating factor) market are focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For example, in 2022, Evive Biotech, a Singapore-based biopharmaceutical company collaborated with Germany based pharmaceutical company, APOGEPHA to enter into an exclusive long-term license agreement for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a novel dimeric G-CSF long-acting fusion protein without pegylation.

G-CSF (Granulocyte Colony Stimulating Factors) Market Players
Major companies operating in the g-csf (granulocyte colony stimulating factors) market report are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd, BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2023. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. G-CSF (Granulocyte Colony Stimulating Factors) Market Report Structure
3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies
4. G-CSF (Granulocyte Colony Stimulating Factors) Market - Macro Economic Scenario
5. G-CSF (Granulocyte Colony Stimulating Factors) Market Size And Growth
…..
27. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.